Autologous wound care
Platelet-rich plasma, without the centrifuge.
Applied PRP is developing a point-of-care platform that concentrates platelets from a patient's own blood with no centrifuge, built for the clinics that treat chronic wounds every day. Platelets are packed with natural growth factors that signal the body to rebuild tissue, which helps restart healing in wounds that have stalled.
In development · Not FDA cleared
Red blood cells settle out by sedimentation. Platelet-rich plasma is drawn off the top. No centrifuge.
The problem
Chronic wounds are common, costly, and slow to close.
Diabetic foot ulcers, venous leg ulcers, and pressure injuries often stall for months under standard care. Autologous PRP is a recognized option for chronic non-healing wounds, and Medicare covers it for those indications.2
Yet PRP remains a small part of advanced wound care. Producing it today means a centrifuge: capital equipment, space, staff training, and extra time in a busy outpatient visit. Many wound clinics never adopt it.
The gap
Centrifuge-free products exist. Centrifuge-free PRP does not.
| Centrifuge PRP systems | Whole blood clot systems | Applied PRP (target) | |
|---|---|---|---|
| Concentrates platelets | Yes | No | Yes |
| Needs a centrifuge | Yes | No | No |
| Uses the patient's own blood | Yes | Yes | Yes |
| Prepared at point of care | Yes | Yes | Yes |
Whole blood clot devices are already centrifuge-free and FDA 510(k) cleared, but they don't concentrate platelets. To our knowledge, no cleared device produces concentrated platelet-rich plasma without a centrifuge.3 That is the space we're building for.
The platform
Designed around the wound clinic, not the lab.
Autologous
Starts and ends with the patient's own blood. Nothing donor-derived, nothing stored.
Point of care
A single-use kit meant to fit inside a normal visit, with no capital equipment on the counter.
Built for 510(k)
Developed from day one against an established Class II device framework for blood processing.
Commercialization
Built for where wound care is going: mobile.
CMS code
G0465 Autologous PRP for chronic non-healing wounds2Reimbursement · office
$2,108 per application, physician office (2025 national rate)6Reimbursement · hospital outpatient
$1,064 per application, hospital outpatient department (2025)6Reimbursement
Skin substitute payment has been reset
Medicare spending on skin substitutes went from about $256 million in 2019 to over $10 billion in 2024.4 Starting in 2026, CMS pays most of them as supplies at a flat rate of about $127 per cm², and expects that to cut spending by more than half.4 The money has come out of skin subs.
Customer
Mobile wound care providers
Mobile wound care, treating patients at home and in nursing facilities, has been the fastest-growing part of the field, and home care saw some of the largest increases in skin substitute use.5 Those providers now need therapies that keep this care setting affordable.
Market approach
Primary competitor: whole blood clot
In mobile wound care, whole blood clot systems are the only blood-based option in use today, because they don't need a centrifuge. But a whole blood clot isn't PRP. Applied PRP delivers true platelet-rich plasma, with platelets concentrated above what's in whole blood, in the same centrifuge-free, bedside format.
Mobile wound care is our primary market. The existing PRP wound care market, in clinics and hospital outpatient departments, is a secondary market for the same kit.
Path to market
Where we are, and what comes next.
-
Now
Platform development
Red blood cell capture proven in the lab. Now refining it into a point-of-care kit.
-
Next
Verification & submission
Design verification, performance testing, and 510(k) preparation.
-
Then
Clearance & launch
Bringing the kit to U.S. wound care providers.